| PI3K/AKT/mTOR信号通路抑制剂在淋巴瘤中的研究进展* |
| |
| 引用本文： | 刘慧, 李鑫, 胡腾鹏, 孙振昌, 张明智. PI3K/AKT/mTOR信号通路抑制剂在淋巴瘤中的研究进展*[J]. 中国肿瘤临床, 2016, 43(5): 211-215. DOI: 10.3969/j.issn.1000-8179.2016.05.388 |
| |
| 作者姓名： | 刘慧 李鑫 胡腾鹏 孙振昌 张明智 |
| |
| 作者单位： | 作者单位:郑州大学第一附属医院肿瘤内科(郑州市450000) |
| |
| 基金项目： | and the Science and Technology Key Project of Henan Province (No.340600531502)*本文课题受国家自然科学基金项目(编号8157010926)，河南省科技厅创新人才项目、河南省科技开放合作项目、河南省科技重点项目(编号340600531502) |
| |
| 摘 要： | 磷脂酰肌醇-3 激酶（phosphatidylinositol 3-kinase，PI 3K）- 蛋白激酶B（protein kinaseB ，PKB ，又称AKT ）- 雷帕霉素靶蛋白（mammalian target of rapamycin，mTOR）信号通路与细胞的生长、增殖、分化、凋亡、代谢等密切相关，在多种实体肿瘤中已发现该信号通路的异常。近年来，以抑制该通路特定位点的靶向治疗已成为抗肿瘤的研究热点。许多该位点新型抑制剂也已进入淋巴瘤的临床试验中，本文就该通路在淋巴瘤中的活化状态及各个分子靶点抑制剂的研究进展做一综述。
|
| 关 键 词： | 淋巴瘤 信号转导 PI 3K/AKT/mTOR 信号通路 靶向治疗 |
| 收稿时间： | 2015-12-15 |
| 修稿时间： | 2016-01-29 |
Research progress on PI3K/AKT/mTOR signal pathway in lymphoma |
| |
| Hui LIU, Xin LI, Tengpeng HU, Zhenchang SUN, Mingzhi ZHANG. Research progress on PI3K/AKT/mTOR signal pathway in lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(5): 211-215. DOI: 10.3969/j.issn.1000-8179.2016.05.388 |
| |
| Authors: | Hui LIU Xin LI Tengpeng HU Zhenchang SUN Mingzhi ZHANG |
| |
| Affiliation: | Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou450000, China |
| |
| Abstract: | The phosphoinositide-3 kinase (PI3K)/protein kinase B (PKB/AKT)/mammalian target of rapamycin (mTOR) pathway is asso-ciated with cell growth, proliferation, differentiation, apoptosis and metabolism. The abnormalities of this signal pathway are found in various malignant tumors. This pathway has also been investigated as an anti-tumor target. Recently, novel inhibitors have been stud-ied in clinical trials of lymphoma. This review summarizes the activation status of the PI3K/AKT/mTOR pathway and its use for targeted therapy of lymphoma. |
| |
| Keywords: | lymphoma signal transduction PI3K/Akt/mTOR signal pathway targeted therapy |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
